The Food & Drug Administration approved Medtronic Inc.’s (NYSE:MDT) MRI-safe pacemaker, touted as the first such device to hit the market.
The Minneapolis-based medical device giant said it plans to begin shipping the product immediately.
The Revo MRI SureScan pacing system is the "first and only pacemaker system in the U.S. specifically designed for use in an magnetic resonance imaging environment,"according to the company.
An FDA advisory panel recommended that the agency approve the device in March of last year.
About 200,000 people implanted with pacemakers must forego MRI scans every year in the U.S. because of the danger of serious adverse events. The magnetic field from the MRI machine can disrupt a pacemaker’s ability to function and regulate the patient’s heartbeat. Prior to an MRI scan, a patient implanted with a Revo pacemaker must have it programmed to withstand the magnetic energy, according to the company.
There are about 5 million people worldwide implanted with pacemakers and implantable cardioverter-defibrillators, according to Medtronic, while there are about 30 million MRI scans per year.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.